In the CLL11 study, published 2014 in NEJM chlorambucil-obinituzumab showed significant PFS benefit over chlorambucil- rituximab in patients with CLL. The median PFS was 26.7 vs 15.2. In the initial publication there was no OS benefit of obi vs Rituxan, however in the final OS analysis in 2018 a OS benefit was seen with a HR of 0.76.
Under the terms of the agreement, PathAI will make its AISight image management system available to pathology labs on the Google Cloud.
Provided to YouTube by Epic/LegacyOhio / Machine Gun · The Isley BrothersGivin’ It Back℗ Originally released 1971. All rights reserved by Sony Music Entertai…
Researchers from the University of Cologne have found a new use for cnicin, a substance produced in blessed thistle. Their article “Cnicin promotes functional nerve…
A Manitoba woman thought she found a miracle natural supplement, but said a hidden ingredient wreaked havoc on her health.
A regulatory decision is expected on February 14, 2025.
University of California, San Francisco (UCSF) scientists have discovered a precursor in the blood of some people who later went on to develop multiple sclerosis…
You can leave your personal vendettas at home – we have work to do, Pichai warns
An abstract is unavailable.
The physical signs of an eating disorder aren’t always the right or only signs to look out for. A psychologist and obesity specialist explains how…
Espousing his ideas in best sellers, he insisted that religion was an illusion, free will was a fantasy and evolution could only be explained by…
